Skip to main content
. 2017 Apr 20;8(42):71489–71499. doi: 10.18632/oncotarget.17288

Figure 7. CVV induced complete regression of liver tumorigenicity and metastasis to colon.

Figure 7

(A) The metastasis of liver-injected Sk-Hep-1 cells to colon in Sorafenib, CVV or CVV+sorafenib treatment group. Four weeks after treatment (n = 4 in each group), metastatic regions were rare in the CVV-treated groups (i.e., CVV or sorafenib with CVV), whereas metastatic regions remained in the sorafenib-treated regions. (B) Hematoxylin and eosin staining and Tunnel assay results. (C) Number of liver tumor polyps, changed lobes, colorectal metastasized polyps observed in each mouse. (n = 4), *p < 0.0001. The complete regression of liver tumorigenicity and colorectal metastasis in the CVV-treated groups. CVV, cancer-favoring engineered vaccinia virus; PBS, phosphate-buffered saline; i.p., intraperitoneal; p.o., oral administration.